EUVIMEDEUVIMED entdecken
Open Access

CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms

Umar Wazir, Amber X Li, Carolyn Cai Wang, Henson Han Gao, Tracey A Martin, Wen G Jiang, Kefah Mokbel

Cancer Genomics - Proteomics · 2025

DOI: 10.21873/cgp.20521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2025. Verfasst von Umar Wazir und 6 weiteren Autor:innen. Beteiligte Einrichtung: The London Breast Institute, Princess Grace Hospital, London, U.K. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Antigens, Differentiation, B-Lymphocyte, Breast Neoplasms, B7-H1 Antigen. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Cluster of differentiation 84 (CD84), a member of the signalling lymphocytic activating molecule (SLAM) family, has emerged as a potential prognostic biomarker and therapeutic target in breast cancer. This study explored CD84 expression and its correlation with clinicopathological features in a well-characterised cohort. MATERIALS AND METHODS: Using quantitative real-time PCR, mRNA expression levels of CD84 and related molecules, including PDL1, CD74, and other immune tolerance markers, were analysed. RESULTS: The findings reveal that elevated CD84 expression predicts poor overall survival, independent of conventional prognostic factors such as the Nottingham Prognostic Index (NPI). Notably, a combined signature of CD84, CD48, VAV1, and CTNNB1 demonstrated stronger prognostic power than individual markers. CD84 exhibited significant correlations with immunosuppressive molecules, including PDL1 and CD74, underscoring its role in fostering immune tolerance within the tumour microenvironment. CONCLUSION: CD84 may mediate an immunosuppressive phenotype, facilitating immune evasion in breast cancer. This highlights its potential as a therapeutic target, particularly in triple-negative breast cancer, to overcome immune resistance and enhance treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorAntigens, Differentiation, B-LymphocyteBreast NeoplasmsB7-H1 AntigenImmune ToleranceHistocompatibility Antigens Class IISignaling Lymphocytic Activation Molecule FamilyHumansFemalePrognosisMiddle AgedAdultTumor MicroenvironmentAged

Stichwörter der Autor:innen

CD48CD74CD84CTNNB1PD-L1TNBCVAV1breast cancercheckpoint inhibitorsimmune toleranceimmunotherapy

Substanzen

Biomarkers, TumorAntigens, Differentiation, B-Lymphocyteinvariant chainB7-H1 AntigenHistocompatibility Antigens Class IICD274 protein, humanSignaling Lymphocytic Activation Molecule Family

Autor:innen und Institutionen

  • The London Breast Institute, Princess Grace Hospital, London, U.K.
  • Metastasis Research Group, University of Wales College of Medicine, Cardiff, U.K.
  • The London Breast Institute, Princess Grace Hospital, London, U.K.; Kefah.Mokbel@hcahealthcare.co.uk.

Zitieren

APA

Wazir, U., Li, A. X., Wang, C. C., Gao, H. H., Martin, T. A., Jiang, W. G., & Mokbel, K. (2025). CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20521

Vancouver

Wazir U, Li AX, Wang CC, Gao HH, Martin TA, Jiang WG, et al. CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms. Cancer Genomics - Proteomics. 2025. doi:10.21873/cgp.20521

BibTeX
@article{Wazir2025,
  author = {Wazir, Umar and Li, Amber X and Wang, Carolyn Cai and Gao, Henson Han and Martin, Tracey A and Jiang, Wen G and Mokbel, Kefah},
  title = {CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms},
  journal = {Cancer Genomics - Proteomics},
  year = {2025},
  doi = {10.21873/cgp.20521}
}
Kostenlos starten →